Showing results (71-80 of 251) with videos related to

Sort By:
Pageof 26
BMC Cancer|July 25, 2013
Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective studyAkira Ono, Toshiaki Takahashi, Keita Mori, et al.
Journal of Cancer|June 14, 2018
Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With ChemoradiotherapyHaruki Kobayashi, Tateaki Naito, Katsuhiro Omae, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavityAkira Ono, Haruyasu Murakami, Masakuni Serizawa, et al.
Japanese Journal of Clinical Oncology|January 14, 2009
Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective studyTakehito Shukuya, Toshiaki Takahashi, Akihiro Tamiya, et al.
Japanese Journal of Clinical Oncology|December 17, 2013
A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancerYuki Misumi, Makoto Nishio, Toshiaki Takahashi, et al.
Lung Cancer (Amsterdam, Netherlands)|August 25, 2009
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancerSatoshi Igawa, Reiko Watanabe, Ichiro Ito, et al.
Anticancer Research|July 15, 2009
Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinibTakehito Shukuya, Toshiaki Takahashi, Akihiro Tamiya, et al.
Respiratory Investigation|March 10, 2015
Disease flare after gefitinib discontinuationHiroaki Akamatsu, Akira Ono, Takehito Shukuya, et al.
Medical Oncology (Northwood, London, England)|June 26, 2014
Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapyHisao Imai, Keita Mori, Akira Ono, et al.
Cancer Chemotherapy and Pharmacology|July 20, 2012
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumorsHaruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto, et al.
Pageof 26